The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2026
Filed:
Oct. 04, 2022
Applicant:
Astrazeneca Ab, Sodertalje, SE;
Inventors:
Magnus Polla, Sodertalje, SE;
Joakim Bergman, Sodertalje, SE;
Johan Sundell, Sodertalje, SE;
Jonas Brånalt, Sodertalje, SE;
Ekaterina Ratkova, Sodertalje, SE;
Johan Kajanus, Sodertalje, SE;
Magnus Johansson, Sodertalje, SE;
Assignee:
ASTRAZENECA AB, Sodertalje, SE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 491/048 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 491/048 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01);
Abstract
There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.